Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023
Enveric Biosciences, Inc. (ENVB)
Company Research
Source: Business Wire
Product Development Highlights:Selected neuroplastogen lead candidate EB-003, a potential first-in-class therapeutic option for addressing difficult-to-treat mental health disorders by promoting neuroplasticity without inducing hallucinations.Started IND-enabling preclinical activities for EB-002 and completed important repeat-dose toxicology studies, genotoxicity studies, and key cardiac, respiratory, and CNS safety pharmacology studies.Corporate and Business Development Highlights:Signed three non-binding term sheets with an undisclosed biotechnology company to pursue the out-licensing of three classes of compounds from the Company’s extensive portfolio of assets.Signed two additional non-binding term sheets with a second undisclosed biotechnology company to pursue the out-licensing of pharmaceutical and non-pharmaceutical applications of cannabinoid conjugate compounds.Expanded intellectual property portfolio through Q1 2024 with seven patent issuances protecting composition of mat
Show less
Read more
Impact Snapshot
Event Time:
ENVB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ENVB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ENVB alerts
High impacting Enveric Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
ENVB
News
- Enveric Biosciences, Inc. (ENVB) Stock Declines While Market Improves: Some Information for Investors [Yahoo! Finance]Yahoo! Finance
- What Makes Enveric Biosciences (ENVB) a New Strong Buy Stock [Yahoo! Finance]Yahoo! Finance
- Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023 [Yahoo! Finance]Yahoo! Finance
- Enveric gains on out-licensing deal of new chemical entities for joint disease treatments [Seeking Alpha]Seeking Alpha
- Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease [Yahoo! Finance]Yahoo! Finance
ENVB
Analyst Actions
- 1/30/24 - HC Wainwright
ENVB
Sec Filings
- 4/16/24 - Form ARS
- 4/16/24 - Form DEF
- 3/28/24 - Form 8-K
- ENVB's page on the SEC website